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criteria to improve selectivity of patients for renal artery interventions
remains to be determined.
Asymptomatic Peripheral Arterial Disease is Associated with More
Adverse Lower Extremity Characteristics than Intermittent Claudication
McDermott MN, Guralnik JN, Ferrucci L, et al. Circulation 2008;117:
2484-92.
Conclusion: Persons with peripheral arterial disease (PAD) who do
not have exertional leg symptoms have poorer functional outcomes, poorer
quality of life, and more adverse calf muscle characteristics compared with
subjects without PAD who are sedentary and asymptomatic , and when
compared with subjects with intermittent claudication.
Summary: The study sought to assess calf muscle characteristics,
peripheral nerve function, functional performance, and quality of life in
patients with PAD who are asymptomatic. The study included 465 patients
with PAD. PADwas defined as an ankle-brachial index of0.90. There were
292 non-PAD participants who had ankle-brachial indices of0.90 to 1.30.
Patients with PAD were subcategorized into 215 with leg symptoms and
those who were always asymptomatic, and 72 PAD patients who never
experienced exertional leg pain even during a 6-minute walk test. Computed
tomography scanning was used to evaluate calf muscles. Subjects also
underwent peroneal nerve conduction velocity testing to evaluate motor
nerves, and sural nerve testing to evaluate lower extremity sensory nerves.
Upper extremity motor nerves were evaluated using ulnar nerve conduction
velocities. All analyses were adjusted for race, sex, age, ankle-brachial index,
comorbidities, and other potential confounders.
Compared with participants with intermittent claudication, always
asymptomatic PAD patients had smaller calf muscle area (P .001), higher
calf muscle percent fat (16.1% vs 9.45%; P  .001), worse 6-minute walk
performance (P  .0002), slower usual paced walking speed (P  .0019),
slower fast paced walking speed (P .001), and poorer physical functioning
score (P  .016) on the Medical Outcomes Study Short-Form 36 Health
Survey. When all these asymptomatic PAD patients were compared with an
age-matched sedentary non-PAD cohort, PAD participants had smaller calf
muscle area (P .009), poorer 6-minute walk performance (P .001), and
poorer walking impairment questionnaire speed scores (P  .001).
Comment: The asymptomatic patient with PAD is coming under
increasing scrutiny. This study breaks new ground in examining anatomic
characteristics of subgroups of patients with PAD. This study has a number
of limitations that are acknowledged by the authors, probably the most
important of which is that the data is cross-sectional and therefore any
association between variables cannot be construed as causal. Nevertheless, it
is fascinating that patients with always-asymptomatic PAD have quantifiable
adverse calf muscle characteristics compared with sedentary asymptomatic
age-matched non-PAD subjects and symptomatic PAD subjects. This will
only be the first of a number of future studies examining the anatomic
characteristics of varying symptomatic levels of PAD.
Clinical Predictors for Fatal Pulmonary Embolism in 15,520 Patients
with Venous Thromboembolism: Findings from the Registro Informa-
tizado de la Enfermedad Thrombo Embolica Venosa (RIETE) Registry
Laporte S, Mismetti P, Decousus H, and the RIETE Investigators. Circu-
lation 2008;117:1711-6.
Conclusion: Predictors for fatal pulmonary embolism (PE) include
massive PE, nonmassive symptomatic PE, immobilization for neurologic
disease, age 75 years, and the presence of cancer.
Summary: The authors used data from the Registro Informatizado de
la Enfermedad Thrombo Embolica Venosa (RIETE) Registry to determine
independent predictive factors for fatal PE. The RIETE Registry is an
international multicenter observational prospective registry of consecutive
patients with objectively confirmed symptomatic acute venous thromboem-
bolism (VTE). Treatment of patients is managed according to the clinical
practice of each participating center. Each center has registry coordinator for
data collection and quality control. Information collected includes demo-
graphic data, symptoms on presentation, type of VTE, types and results of
diagnostic methods, risk factors for VTE, and therapeutic management of
both the acute phase and subsequent 3 months. In the present study, fatal
pulmonary embolism was the outcome analyzed.
Between March 2001 and July 2006, 15,520 consecutive patients
(mean age, 66.3  16.9 years; 49.7% men) with acute VTE were included.
Symptomatic deep venous thrombosis without symptomatic PE was ob-
served in 9008 patients (58%). Nonmassive symptomatic PE was present in
6264 (40.4%), and massive symptomatic PE was present in 248 (1.6%). At 3
months, the cumulative rates of overall mortality and fatal PE were 8.65%
and 1.68%. Using multivariable analysis, the authors determined symptom-
atic nonmassive PE at presentation provided a 5.42-fold higher risk of fatal
PE compared with patients with DVT without symptomatic PE (P .001).
There was a 17.5-times increase of the risk of fatal PE in patients with a
symptomatic massive PE. Immobilization for neurologic disease, age 75years, and cancer were also other clinical factors independently associated
with an increased risk of fatal PE.
Conclusion: The data indicate that if you initially survive a massive PE,
you are likely to survive for a longer term: 50% and 75% of the deaths directly
attributed to PE occurred within 5 and 12 days, respectively, of the massive
PE. It is a bit surprising that this study did not find cardiac or respiratory
insufficiency to be predictive of death from PE. This may reflect insufficient
numbers or more likely is a function of the type of data available in a registry
where no specific testing was mandated or systematically performed of
cardiac and pulmonary functional status.
Effect of Clopidogrel on Early Failure of Arterial Venous Fistula for
Hemodialysis: A Randomized, Controlled Trial
Nember LM, Beck GJ, Allon M, for The Dialysis Access Consortium Study
Group. JAMA 2008;299:2164-2171.
Conclusion: Clopidogrel reduces early thrombosis of new arterio-
venous fistulas but does not increase the proportion of fistulas that ultimately
become suitable for dialysis.
Summary:Antiplatelet agents may reduce thrombosis of newly created
arteriovenous fistulas. Fistula thrombosis is one of a number of barriers to
achieving autogenous access in patients requiring hemodialysis. In this study
the authors sought to determine whether clopidogrel could reduce early
failure of new fistulas created for hemodialysis access.
This was a randomized, double-blind, placebo-controlled trial con-
ducted at nine United States centers that represented both academic and
community practices. The study period was from 2003 through 2007,
during which 877 participants with advanced chronic kidney disease or
end-stage renal disease were followed up until 150 to 180 days after fistula
creation, or until 30 days after initiation of dialysis, whichever occurred later.
Participants were randomly assigned to receive clopidogrel or placebo.
Clopidogrel-treated patients received a 300-mg loading dose, followed by a
daily dose of 75 mg (n  441). The drugs were administered for 6 weeks,
starting 1 day after fistula creation. The primary outcome was fistula
thrombosis determined by physical examination at 6 weeks. The secondary
outcome was failure of the fistula to become suitable for dialysis. Suitability
for dialysis was defined as the fistula providing 300 mL/min of flow during
8 of 12 dialysis sessions.
Based on the stopping rule for intervention efficacy, enrollment in the
study was stopped after 877 patients had been randomized. Fistula thrombosis
occurred in 53 (12.3%) of those assigned to clopidogrel compared with 85
(19.5%) of those assigned to placebo (relative risk, 0.63; 95% confidence
interval, 0.46-0.97, P .018). There was, however, no difference in failure to
attain suitability for dialysis in the clopidogrel and placebo groups, at 61.8% vs
59.5% respectively (relative risk, 1.05; 95% confidence interval, 0.94-1.17; P
.40). There was no increase in bleeding events with the use of clopidogrel.
Comment: Obviously, early patency is necessary for fistula matura-
tion. However, there are clearly other aspects of fistula maturation
required for the fistula to ultimately be useful for dialysis. Distal stenoses
in the draining vein and poor arterial inflow can limit successful fistula
maturation despite the use of an antiplatelet agent to prevent early
thrombosis. Another key to fistula maturation may be surgical judgment.
This study will be limited in its effect by the high rate of fistula failure that
was observed. The trial points out the need to identify other mechanisms
for failure of fistula maturation and for improved criteria for selecting
candidates for fistula creation.
Embolic Protection in Platelet Inhibition during Renal Artery Stenting
Cooper CJ, Haller ST, Colyer W, et al. Circulation 2008;117:2752-60.
Conclusion:Renal artery stenting alone, stenting in combinationwith abcix-
imab,andstentingwithembolicprotectionall resulted inadecline in theglomerular
filtration rate (GFR).However, with a combination of renal protectionwith a filter
device and abciximab, the GFR did not decline after renal artery stenting.
Summary: Atheroembolization can result in renal dysfunction during
renal artery stenting procedures. It is unknown, however, whether a use of
embolic protection devices or glycoprotein II-B/III-A inhibitors may result
in preservation of renal function after renal artery stenting.
In this study, 100 patients undergoing renal artery stenting at seven
centers were randomly assigned in an open-labeled trial investigating the
efficacy of the AngioGuard (Cordis, Miami Lakes, Fla) embolic protection
device and the platelet glycoprotein II-B/III-A inhibitor abciximab. A
two-by-two factorial design was used. Abciximab was administered in a
double-blind fashion. The GFR was calculated from the modified Modifi-
cation in Diet and Renal Disease equation and was the primary measure of
renal function. Patients were instructed to drink 1 L of water the day
before and 500 mL of water the morning of creatinine assessment. Filter
devices were analyzed for the presence of platelet-rich thrombus.
With stenting alone, stenting with abciximab alone, and stenting with
embolic protection, the GFR declined (P  .05). With a combination of
embolic protection and abciximab, the GFR did not decline and was
superior to other allocations in the two-by-two design (P  .01). The main
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though abciximabwas superior to placebo (0%27% vs –10%20%;P .05).
Embolic protection was not superior to placebo (–1%  28% vs –10%  20%;
P .08). The interaction favoring the combination of abciximab and embolic
protection was significant (P .05). The occurrence of platelet-rich emboli
in the embolic protection filters decreased with abciximab from 42% to 7%
(P  .01).
Comment: The lack of efficacy of the embolic protection device in
improving the GFR after renal artery stenting despite capturing debris
suggests that emboli from before or after filter deployment, or alternativemechanisms to renal injury, offset the efficacy of the embolic protection
device when used in isolation. Abciximab may work by decreasing emboli to
the kidney before deployment of the filter device or perhaps reducing
adverse effects of platelet activation in ischemia-induced renal dysfunction.
It is important to keep in mind that the end points in this study are merely
surrogate end points for the more clinically important end points of long-
term blood pressure control and renal preservation. Whether the use of
embolic protection devices and glycoprotein II-B/III-A platelet inhibitors
favorably influence these more important clinical parameters after renal
artery stenting is yet to be determined.
